Page last updated: 2024-12-07
jietacin a
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
jietacin A: isolated from a streptomycete; MF C18-H34-N2-O2; azoxy cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 131028 |
| CHEMBL ID | 4446187 |
| MeSH ID | M0151070 |
Synonyms (8)
| Synonym |
|---|
| 109766-61-2 |
| 8-pentadecanone, 1-(ethenyl-onn-azoxy)-14-methyl- |
| 1-(ethenyl-onn-azoxy)-14-methyl-8-pentadecanone |
| brn 5538455 |
| jietacine a |
| jietacin a |
| ethenyl-(14-methyl-8-oxopentadecyl)imino-oxidoazanium |
| CHEMBL4446187 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (4)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1568279 | Antiproliferative activity against human ATN1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Jietacins, azoxy natural products, as novel NF-κB inhibitors: Discovery, synthesis, biological activity, and mode of action. |
| AID1568280 | Antiproliferative activity against human K562 cells assessed as reduction in cell viability at 10 ug/ml measured after 24 hrs by MTT assay relative to control | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Jietacins, azoxy natural products, as novel NF-κB inhibitors: Discovery, synthesis, biological activity, and mode of action. |
| AID1568277 | Inhibition of NF-kappaB localization in nucleus of human L540 cells at 10 ug/ml measured after 5 to 24 hrs by DAPI staining immunofluorescence microscopy | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Jietacins, azoxy natural products, as novel NF-κB inhibitors: Discovery, synthesis, biological activity, and mode of action. |
| AID1568284 | Inhibition of TNF alpha stimulated NF-kappaB in human FL cells transfected with kappaB luciferase at 5 to 10 ug/ml incubated for 4 hrs followed by TNF alpha stimulation measured after 3 hrs by dual luciferase reporter gene assay | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Jietacins, azoxy natural products, as novel NF-κB inhibitors: Discovery, synthesis, biological activity, and mode of action. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.42
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.42) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||